CHINA
A privately owned conglomerate buys a majority stake in Dendreon, the troubled developer of prostate cancer treatment Provenge (sipuleucel-T), for $819.9 million cash. In 2015, Canadian pharma Valeant paid Dendreon $495 million to take the biotech out of Chapter 11 bankruptcy. Valeant is now selling its stake in Seattle-based Dendreon to Sanpower Group of Nanjing, Jiangsu Province.
EGYPT
The country's military receives the go-ahead to produce pharma products following a decree by Prime Minister Sherif Ismail. The resolution allows the National Agency for Military Production to establish a pharma company called the Egyptian National Company for Pharmaceuticals. The announcement did not provide details of the types of medicines that will be produced, but the decree is an attempt to counter drug shortages and increasing prices in the past year.
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Stephen Quake
Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced. http://www.nature.com/nbt/podcast/index.html N E W S
